Dendrimers for Enhanced Drug Solubilization

Drug Delivery Strategies for Poorly Water-Soluble Drugs

Volumn , Issue , 2013, Pages 373-409

  Jain, Narendra K ^a   Tekade, Rakesh K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Dendrimer; Dendrimer biocompatibility and toxicity; Dendrimer biomedical applications; Dendrimer generations; Dendrimer mediated solubilisation; Dendritic box; Drug dendrimer conjugation; Host guest interactions; PEGylated dendrimer; PH responsive dendrimer

Indexed keywords

EID: 84885666145     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118444726.ch13     Document Type: Chapter

References (158)

1. R.J. Boghra, P.C. Kothawade, V.S. Belgamwar, et al., Solubility, dissolution rate and bioavailability enhancement of irbesartan by solid dispersion technique, Chem Pharm Bull, 59, 438-441 (2011).
2. M. Vogt, K. Kunath, J.B. Dressman, Dissolution enhancement of fenofibrate by micronization, cogrinding and spray drying: Comparison with commercial preparations, Eur J Pharm Biopharm, 68, 283-288 (2008).
3. F. Guo, H. Zhong, J. He, et al., Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: Preparation and evaluation, Arch Pharm Res, 34, 1113-23 (2011).
4. P. Sharma, W.A. Denny, S. Garg, Effect of wet milling process on the solid state of indomethacin and simvastatin, Int J Pharm, 380, 40-48 (2009).
5. C.Y. Wu, L.Z. Benet, Predicting drug disposition via application of BCS: transport/ absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system, Pharm Res, 22, 11-23 (2005).
6. J.S. Valentino, W.N. Kwame, Prodrug strategies to overcome poor water solubility. Adv Drug Del Rev., 59, 677-694 (2007).
7. Y.G. Bachhav, V.B. Patravale, Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation, Acta Pharm, 60, 153-163 (2010).
8. S.N. Pace, G.W. Pace, L. Parikh, et al., Novel injectable formulations of insoluble drugs, Pharm Tech, 23, 116-134 (1999).
9. P. Lakshmi, K.G. Ashwini, Nanosuspension technology: A review. Int J Pharm Sci, 2, 35-40 (2010).
10. P.J. Flory, Molecular size distribution in three dimensional polymers. II. Trifunctional Branching Units, J Am Chem Soc, 63, 3091-3096 (1941).
11. P.J. Flory, Crystallinity and dimensional changes in fibrous proteins, J Cell Physiol Suppl, 49, 175-183 (1957).
12. P.J. Flory, Conformations of macromolecules, Brookhaven Symp Biol, 13, 89-103 (1960).
13. W.W. Graessley, Statistical mechanics of random coil networks, Macromolecules, 8, 186-190 (1975).
14. P.J. Flory, Fundamental principles of condensation polymerization, Chem Rev, 39, 137-197 (1946).
15. P.J. Flory, Molecular size distribution in three dimensional polymers. VI. Branched polymers containingA-R-Bf-1 Type Units, J Am Chem Soc, 74, 2718-2723 (1952).
16. F. Vogtle, S. Gestermann, R. Hesse, et al., Functional dendrimers, Prog Polym Sci, 25, 987-1041 (2000).
17. D.A. Tomalia, H. Baker, J. Dewald, et al., Anewclass of polymers: starburst-dendritic macromolecules, Polym J, 17, 117-132 (1985).
18. J.M.J. Fréchet. Functional polymers and dendrimers: Reactivity, molecular architecture, and interfacial energy, Science, 263, 1710-1715 (1994).
19. A.K. Zimmerman, P. Chetoni, M.F. Saettone, Evaluation of pilocarpine-loaded albumin particles as controlled drug delivery systems for the eye. II. Co-administration with bioadhesive and viscous polymers. J Cont Rel, 33, 31-46 (1995).
20. E.C.Wiener, S.Konda, A. Shadron, et al., Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor, Invest. Radiol, 32, 748-754 (1997).
21. J.R. Baker, A. Quintana, L.T. Riehler, et al., The synthesis and testing of anti-cancer therapeutic nanodevices: Biomed, Microdevices, 3, 61-69 (2001).
22. A. Quintana, E. Raczka, L. Piehler, et al., Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor, Pharm Res, 19, 1310-1316 (2002).
23. R.K. Tekade, P.V. Kumar, N.K. Jain, Dendrimers in oncology: An expanding horizon, Chem Rev, 109, 49-87 (2009).
24. G.R. Newkome, C.N. Moorefield, J.N. Keith, et al., Escamilla, Chemistry within a unimolecular micelle precursor: Boron superclusters by site-and depth-specific transformations of dendrimers, Angew Chem, Int Ed, 33, 666-668 (1994).
25. J. Issberner, R. Moors, Dendrimers: From generations and functional groups to functions, Angew Chem, Int Ed Engl, 33, 2413-2420 (1994).
26. R.F. Service, Dendrimers: Dream molecules approach real applications, Science, 267, 458-459 (1995).
27. R. Esfand, D.A. Tomalia, Poly (amidoamine) (PAMAM) dendrimers: From biomimicry to drug delivery and biomedical applications, Drug Disc Today, 6, 427-436 (2001).
28. G.R. Newkome, C.N. Moorefield, G.R. Baker, et al., Unimolecular micelles, Angew Chem, Int Ed Engl, 30, 1176-1178 (1991).
29. G.M. Dykes, Dendrimers: A review of their appeal and applications, J Chem Technol Biotechnol, 76, 903-918 (2001).
30. M. Liu, J.M.J. Fréchet, Designing dendrimers for drug delivery. Pharm Sci Technol, Today, 2, 393-401 (1999).
31. E. Buhleier, W. Wehner, F. Vogtle, "Cascade"-and "Nonskid-Chain-like" synthesis of molecular cavity topologies, Synthesis, 3, 155-158 (1978).
32. K. Autumn, Y.A. Liyang, S.T. Hseih, et al., Adhesive force of a single gecko foot-hair, Nature, 405, 681-685 (2000).
33. U. Boas, P.M. Heegaard, Dendrimers in drug research, Chem Soc. Rev, 33, 43-63 (2004).
34. D.A. Tomalia, H. Baker, J. Dewald, et al., Dendritic macromolecules: Synthesis of starburst dendrimers, Macromolecules, 19, 2466-2468 (1986).
35. D.A. Tomalia, Starburst dendrimers-nanoscopic supermolecules according to dendritic rules and principles. Macromol Symp, 101, 243-255 (1996).
36. G.R. Newkome, Z. Yao, G.R. Baker, et al., Cascade molecules: A new approach to micelles, J Org Chem, 50, 2003 (1985).
37. P. Singh, U. Gupta, A. Asthana, et al., Folate and Folate-PEG-PAMAM dendrimers: Synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. BioconJ Chem, 19, 2239-2252 (2008).
38. C.J. Hawker, J.M.J. Fréchet, Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules, J Am Chem Soc, 112, 7638-7647 (1990).
39. D.A. Tomalia, A.M. Naylor, W.A. Goddard III, Starburst dendrimers: Molecular level control of size, shapes, surface chemistry, topology and flexibility from atoms to macroscopic matter, Angew Chem, Int Ed, 29, 138-175 (1990).
40. D. Fischer, Y. Li, B. Ahlemeyer, et al., In vitro cytotoxicity testing of polycations: Influence of polymer structure on cell viability and hemolysis, Biomaterials, 24, 1121 (2003).
41. A.W. Bosman, H.M. Janssen, E.W. Meijer, About dendrimers: Structure, physical properties, and applications, Chem Rev, 99, 1665-1688 (1999).
42. C.J. Hawker, K.L. Wooley, J.M.J. Fréchet, Unimolecular micelles and globular amphiphiles: Dendritic macromolecules as novel recyclable solubilization agents, J Chem Soc, 21, 1287-1297 (1993).
43. S. Svenson, D.A. Tomalia, Dendrimers in biomedical applications: reflections on the field. Adv Drug Deliv Rev, 57, 2106-2129 (2005).
44. G. Kong, R.D. Braun, M.W. Dewhirst, Hyperthermia enables tumor-specific nanoparticle delivery: Effect of particle size, Can Res, 60, 4440-4445 (2001).
45. M. Liu, K. Kono, J.M.J. Fréchet, Water-soluble dendrimer-polyethylene glycol starlike conjugates as potential drug carriers, J Polym Sci, 37, 3492-3503 (1999).
46. M. Liu, K.Kono, J.M.J. Fréchet, Water-soluble dendritic unimolecular micelles: Their potential as drug delivery agents, J Cont Rel, 65, 121-131 (2000).
47. H. Namazi, M. Adeli, Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents, Biomaterials, 26, 1175-1183 (2005).
48. G. Caminati, K. Gopidas, A.R. Leheny, et al., Photochemical probes of Starburst® dendrimers and their utilization as restricted reaction spaces for electron transfer processes, Polym Prep, 32, 602 (1991).
49. G. Caminati, N.J. Turro, D.A. Tomalia, Photophysical investigation of Starburst® dendrimers and their interactions with anionic and cationic surfactants, J Am Chem Soc, 112, 8515-8522 (1990).
50. S. Stevelmans, J.C.M. Hest van, J.F.G.A. Jansen, et al., Synthesis, characterization and guest-host properties of inverted unimolecular dendritic micelles, J Am Chem Soc, 118, 7398-7399 (1996).
51. B. Devarakonda, R.A. Hill,W. Liebenberg, et al., Comparison of aqueous solubilization of practically insoluble niclosamide by polyamidoamone (PAMAM) dendrimers and cyclodextrins, Int J Pharm, 300, 193-209 (2005).
52. E. Gong, B. Matthews, T. McCarthy, et al., Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses, Antiviral Res, 68, 139-146 (2005).
53. M. Enomoto, A. Aida, Iron complexes capped with dendrimer-appended triazacyclononanes as the novel spatially encumbered models of non-heme iron proteins, J Am Chem Soc, 124, 6099-6108 (2002).
54. A.S. Chauhan, S. Sridevi, K.B. Chalasani, et al., Dendrimer-mediated transdermal delivery: Enhanced bioavailability of indomethacin, J Cont Rel, 90, 335-343 (2003).
55. U. Gupta, H.B. Agashe, N.K. Jain, Polypropylene imine dendrimer mediated solubility enhancement: Effect of pH and functional groups of hydrophobes, J Pharm Pharm Sci, 10, 358-367 (2007).
56. R.N. Prajapati, R.K. Tekade, U. Gupta, et al., Dendimer-mediated solubilization, formulation development and in vitro-in vivo assessment of Piroxicam, Mol Pharm, 6, 940-950 (2009).
57. B. Devarakonda, R.A. Hill, M.M. DeVilliers, The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine, Int J Pharm, 284, 133-140 (2004).
58. S. Uppuluri, D.R. Swanson, L.T. Piehler, et al., Core-shell tecto(dendrimers), synthesis and characterization of saturated shell models, Adv Mater, 12, 796-800 (2000).
59. L.S. Kaanumalle, J. Nithyanandhan, M. Pattabiraman, et al., Water-Soluble Dendrimers as Photochemical Reaction Media: Chemical Behavior of Singlet and Triplet Radical Pairs Inside Dendritic Reaction Cavities, J Am Chem Soc, 126, 8999-9006 (2004).
60. C. Yiyun, X. Tongwen, Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur J MEd Chem, 40, 1390-1393 (2005b).
61. G. Pistolis, A. Malliaris, Study of poly(propylene imine) dendrimers in water by exciplex formation, Langmuir, 18, 246-251 (2002).
62. H.T. Chen, M.F. Neerman, A.R. Parrish, et al., Cytotoxicity, haemolysis, and acute in vivo toxicity of dendrimer based on melamine, candidate vehicles for drug delivery, J Am Chem Soc, 126, 10044-10048 (2004).
63. H. Lee, Y.B. Lim, J.S. Choi, et al., Polyplexes assembled with internally quaternized PAMAM-OH dendrimer and plasmid DNA have a neutral surface and gene delivery potency, BioconJ Chem, 14, 1214-1221 (2003).
64. J.S. Choi, K. Nam, J. Park, et al., Enhanced transfection efficiency of PAMAM dendrimer by surface modification with l-arginine, J Cont Rel, 99, 445-456 (2004).
65. N. Malik, R.Wiwattanapatapee, R. Klopsch, et al., Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo, J Cont Rel, 65, 133-148 (2000).
66. H.R. Ihre, O.L. Padilla DeJesus, J.L. Peters, et al., Polyester dendritic systems for drug delivery applications: Design, synthesis, and characterization, Bioconj Chem, 13, 443-452 (2002).
67. M. Xyloyiannis, O.L. Padilla DeJesus, J.M.J. Fréchet, et al., PEG-dendron architecture influences endocytic capture and intracellular trafficking, Proc. Int Symp Cont Rel Bioact Mat, 30, 149 (2003).
68. J.L. Lach, J. Cohen, Interaction of pharmaceuticals with Schardinger dextrins. II. Interaction with selected compounds, J Pharm Sci, 52, 137-142 (1963).
69. S.B. La, T. Okano, K. Kataoka, Preparation and characterization of the micelleforming polymeric drug indomethacin-incorporated poly(ethylene oxide)-poly(beta-benzyl L-aspartate) block copolymer micelles, J Pharm Sci, 85, 85-90 (1996).
70. R.K. Tekade, T. Dutta, A. Tyagi, et al., Surface-engineered dendrimers for dual drug delivery: A receptor up-regulation and enhanced cancer targeting strategy, J Drug Target, 16, 758-772 (2008).
71. P. Kolhe, J. Khandare, O. Pillai, et al., Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload, Biomat, 27, 660-669 (2006).
72. P.K. Maiti, T. Cagin, S.T. Lin, et al., Effect of solvent and pH on the structure of PAMAM dendrimers, Macromolecules, 38, 979-991 (2005).
73. A. Asthana, A.S. Chauhan, P.V. Diwan, et al., Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site specific delivery of acidic anti-inflammatory active ingredient, AAPS Pharm Sci Tech, 6, E536-E542 (2005).
74. O.M. Milhem, C. Myles, N.B. McKeown, et al., PAMAM starburst dendrimers as solubility enhancers, Int J Pharm, 197, 239-241 (2000).
75. C. Yiyun, X. Tongwen, Solubility of nicotinic acid in polyamidoamine dendrimer solutions, Eur J MEd Chem, 40, 1384-1389 (2005a).
76. A.K. Patri, I.J. Majoros, J.R. Baker Jr., Dendritic polymer macromolecular carriers for drug delivery, Curr Opin Chem Biol, 6, 466-471 (2002a).
77. A.K. Patri, T. Thomas, J.R. Baker, et al., Antibody-dendrimer conjugate for targeted prostate cancer therapy, Polym. Mater. Sci Eng, 86, 130 (2002b).
78. E.R. Gillies, J.M.J. Fréchet, Development of acid-sensitive copolymer micelles for drug delivery, Pure Appl Chem, 76, 1295-1307 (2004).
79. J.C.M. VanHest, M.W.P.L. Baars, R.C. Elissen, et al., Acid functionalized ampiphiles derived from polystyrene-PPI dendrimers with pH dependent aggregation, Macromolecules, 28, 6689-6691 (1995).
80. M.W.P.L. Baars, E.W. Meijer, Host-guest chemistry of dendritic molecules, Top Curr Chem, 2, 131-182 (2000).
81. A.E. Beezer, A.S.H. King, I.K. Martin, et al., Dendrimers as potential drug carriers: Encapsulation of acidic hydrophobes within water soluble PAMAM derivatives, Tetrahedron, 59, 3873-3880 (2003).
82. W. Chen, D.A. Tomalia, J.L. Thomas, Unusual pH-dependent polarity changes in PAMAM dendrimers: Evidence for pH responsive conformational changes, Macromolecules, 33, 9169-9172 (2000).
83. I. Lee, B.D. Athey, A.W. Wetzel, et al., Structural molecular dynamics studies on polyamidoamine dendrimers for a therapeutic application: Effects of pH and generation, Macromol, 35, 4510-4520 (2002).
84. M. Chai, Y. Niu,W.J. Youngs, et al., Structure and conformation of DAB dendrimers in solution via multidimensional NMR techniques, J Am Chem Soc, 123, 4670-4678 (2001).
85. P. Kolhe, E. Misra, R.M. Kannan, et al., Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers, Int J Pharm 259, 143-160 (2003).
86. D. Bhadra, S. Bhadra, S. Jain, et al., A PEGylated dendritic nanaparticulate carrier of fluorouracil, Int J Pharm, 257, 111-124 (2003).
87. J. Khandare, P. Kohle, S. Kannan, Synthesis, cellular transport, and activity of PAMAM-methylprednisolone conjugates, BioconJ Chem, 16, 1049-1054 (2005).
88. T. Dutta, M. Garg, V. Dubey, et al., Investigation on toxicological profile of surface engineered fifth generation poly (propyleneimine) dendrimers in vivo, Nanotoxicol, 2, 62-70 (2008).
89. A.K. Patri, J.F. Kukowska-Latallo, J.R. Baker Jr., Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and noncovalent drug inclusion complex, Adv Drug Del Rev, 57, 2203-2214 (2005).
90. M.T. Morgan,Y. Nakanishi, D.J. Kroll, et al., Dendrimer-encapsulated camptothecins: Increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro, Can Res, 66, 11913-11921 (2006).
91. R.K. Tekade, T. Dutta, V. Gajbhiye, et al., Exploring dendrimers towards dualdrug delivery: pH responsive simultaneous kinetics, J Microencap, 26, 287-296 (2009).
92. N. Malik, E.G. Evagorou, R. Duncan, Dendrimer-platinate: A novel approach to cancer chemotherapy, Antican Drugs, 10, 767-776 (1999).
93. S.H. Medina, M.E.H. El-Sayed, Dendrimers as carriers for delivery of chemotherapeutic agents, Chem Rev, 109, 3141-3157 (2009).
94. S. Kannan, P. Kolhe, V. Raykova, et al., Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells, J Biomat Sci, 15311-15330 (2004).
95. W. Ke, Y. Zhao, R. Huang, et al. Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system, J Pharm Sci, 97, 2208-2216 (2008).
96. J.F.G.A. Jansen, E.M.M. De Brabander-van den Berg, E.W. Meijer, Induced chirality of guest molecules encapsulated into a dendritic box, Rec Trav Chim, 114, 225-230 (1995a).
97. J.F.G.A. Jansen, E.W. Meijer, E.M.M. De Brabander-van den Berg, The dendritic box: Shape-selective liberation of encapsulated guests, J Am Chem Soc, 117, 4417-4418 (1995b).
98. J.F.G.A. Jansen, E.W. Meijer, E.M.M. De Brabander-van den Berg, Bengal rose-at-dendritic box, Macromol Symp, 102, 27-33 (1996).
99. J.F.G.A. Jansen, E.M.M. De Brabander-van den Berg, E.W. Meijer, Encapsulation of guest molecules into a dendritic box, Science, 266, 1226-1229 (1994).
100. R. Esfand, D.A. Tomalia, A.E. Beezer, et al., Orford, dendripore and dendrilock concepts new controlled delivery strategies, Polym Prep, 41, 1324-1325 (2000).
101. A.C.H. Ng, X. Li, D.P.K. Ng, Synthesis and photophysical properties of nonaggregated phthalocyanines bearing dendritic substituents, Macromolecules, 32, 5292-5298 (1999).
102. A. Bahr, B. Felber, K. Schneider, et al., Dendritic, 1,1'-binaphthalene-derived cleft-type receptors (dendroclefts) for the molecular recognition of pyranosides, Helv Chim Acta, 83, 1346-1376 (2000).
103. A. Adronov, S.L. Gilat, J.M.J. Fréchet, et al., Light harvesting and energy transfer in laser-dye labeled poly(aryl ether) dendrimers, J Am Chem Soc, 122, 1175-1185 (2000).
104. S.M. Grayson, J.M.J. Fréchet, Convergent dendrons and dendrimers: From synthesis to applications, Chem Rev, 101, 3819-3867 (2001).
105. A. D'Emanuele, D. Attwood, Dendrimer-drug interactions, Adv Drug Del Rev, 57, 2147-2162 (2005).
106. J. Haensler, F.C. Szoka, Polyamidoamine cascade polymers mediate efficient transfection of cells in culture, BioconJ Chem, 4, 372-379 (1993).
107. J. Satija, U. Gupta, N.K. Jain, Pharmaceutical and biomedical potential of surface engineered dendrimers, Crit Rev Ther Drug Carrier Syst, 24, 261-315 (2007).
108. K. Kono, H. Akiyama, T. Takahashi, et al., Transfection activity of polyamidoamine dendrimers having hydrophobic amino acid residues in the periphery, Bioconj Chem, 16, 208-214 (2005).
109. S. Ahmad, S. Ozaki, T. Nagase, et al., A facile method for synthesis of N-acyloxymethyl-5-Fluorouracils, as a class of antitumor agents, Chem Pharm, Bull, 35, 4137-4143 (1987).
110. Y. Ohya, H. Kobayashi, T. Ouchi, Design of poly (a-malic acid)-5FU-accharide conjugate exhibiting antitumour activity, React Polym, 15, 153-163 (1991).
111. J. Liao, R.X. Zhuo, Synthesis, hydrolysis, and antitumour activity of conjugates of 5-fluorouracil with poly (L-lysine), Polym J, 25, 401-405 (1993).
112. R.X. Zhou, B. Du, Z.R. Lu, In vitro release of 5-fluorouracil with cyclic core dendritic polymer, J Cont Rel, 57, 249-257 (1999).
113. A. D'Emanuele, R. Jevprasesphant, J. Penny, et al., The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability, J Cont Rel, 95, 447-453 (2004).
114. L. Lachman, H.A. Lieberman, J.L. Kanig, The Theory and Practice of Industrial Pharmacy, IIIrd edition, Bombay: Varghese Publishing House, pp. 457-468 (1991).
115. R. Duncan, N. Malik, Dendrimers: Biocompatibility and potential for delivery of anticancer agents, Proc. Int Symp Cont Rel Bioact Mat, 23, 105-106 (1996).
116. E. Bellis, L. Hajba, B. Kovacs, et al., Three generations of α,γ-diaminobutyric acid modified PPI dendrimers and their cisplatin-type platinum complexes, J BioChem Biophys Meth, 69, 151-161 (2006).
117. O.L. Padilla, H. Ihre, L. Gagne, et al., Polyester dendritic system for drug delivery application: in vitro and in vivo evaluation, Bioconj Chem, 13, 453-461 (2002).
118. S. Gurdag, J. Khandare, S. Stapels, et al., Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines, Bioconj Chem, 17, 275-283 (2006).
119. J.J. Khandare, S. Jayant, A. Singh, et al., Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel, Bioconj Chem, 17, 1464-1472 (2006).
120. R.S. Dhanikula, P. Hildgen, Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of Methotrexate, Biomaterials, 28, 3140-352 (2007).
121. R.S. Dhanikula, A. Argawal, J.F. Bouchard, et al., Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: Enhanced efficacy and intratumoral transport capability, Mol Pharm, 5, 105-116 (2008).
122. R. Jevprasesphant, J. Penny, D. Attwood, et al., Transport of dendrimer nanocarriers through epithelial cells via the trans-cellular route, J Cont Rel, 97, 259-267 (2004).
123. Y.H. Choe, C.D. Conover, D. Wu, et al., Anticancer drug delivery systems: multi-loaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors, J Cont Rel, 79, 55-70 (2002).
124. O. Schiavon, G. Pasut, S. Moro, et al. PEG-Ara-C conjugates for controlled release, Eur J MEd Chem, 39, 123-133 (2004).
125. D. Wang, Synthesis of starlike N-(2-hydroxypropyl)methacrylamide copolymers: potential drug carriers, Biomacromolecules, 1, 313-319 (2000).
126. R.S. Greenfield, T. Kaneko, A. Daues, et al., In vitro evaluation of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone linker, Can Res, 50, 6600-6607 (1990).
127. B. Rihova, T. Etrych, M. Pechar, et al., Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes, J Cont Rel, 74, 225-232 (2001).
128. C.C. Lee, E.R. Gillies, M.E. Ox, et al., A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas, Proc Natl Acad Sci, 103, 16649-16654 (2006).
129. C. Falciani, M. Fabbrini, A. Pini, et al., Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting, Mol Can Ther, 6, 2441-2448 (2007).
130. W. Shi, S. Dolai, S. Rizk, et al., Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAMdendrimer curcumin conjugate for therapeutic applications, Org Lett, 9, 5461 (2007).
131. S. Battah, S. Balaratnam, A. Casas, et al., Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates, Mol Pharm, 6, 876-885 (2007).
132. P.S. Lai, P.J. Lou, C.L. Peng, et al., Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy, J Cont Rel, 122, 39-46 (2007).
133. K. Kono, C. Kojima, N. Hayashi, et al., Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin, Polymer, 29, 1664-1675 (2008).
134. T. Kapp, P. Francke, R. Gust, Investigations on surface modified dendrimers: enzymatic hydrolysis and uptake into MCF-7 breast cancer cells, Chem MEd Chem, 3, 635-641 (2008).
135. R. Jevprasesphant, J. Penny, R. Jalal, et al., The influence of surface modification on the cytotoxicity of PAMAM dendrimers, Int J Pharm, 252, 263-266 (2002).
136. L.D. Margerum, B.K. Campion, M. Koo, et al., Gadolinium(III) D03A macrocycles and PEG coupled to dendrimers: Effect of molecular weight on physical and biological properties of macromolecular magnetic resonance imaging contrast agents, J Alloys Comp, 249, 185-190 (1997).
137. Z. Sideratou, D. Tsiourvas, C.M. Paleos, Solubilization and release properties of PEGylated diaminobutane poly(propylene imine) dendrimers, J Colloid Int Sci, 242, 272-276 (2001).
138. C. Kojima, K. Kono, K. Maruyama, et al., Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs, BioconJ Chem, 11, 910-917 (2000).
139. M. Mannisto, S. Vanderkerken, V. Toncheve, et al., Structure-activity relationships of Poly(L-lysine): Effects of PEGylation and molecular shape on physiochemical and biological properties in gene delivery, J Cont Rel, 83, 169-182 (2002).
140. F. Aulenta,W. Hayes, S. Rannard, Dendrimers: A new class of nanoscopic containers and delivery devices, Eur Polym J, 39, 1741-1771 (2003).
141. S.E. Stiriba, H. Frey, R. Haag, Dendritic polymers in biomedical applications: From potential to clinical use in diagnostics and therapy, Angew Chem Int Ed Engl, 41, 1329-1334 (2002).
142. H. Frey, R. Haag, Dendritic polyglycerol: A new versatile biocompatible material, Rev Mol Biotech, 90, 257-267 (2002).
143. A.R. Borges, C.L. Schengrund, Dendrimers and antivirals: A review. Curr Drug Targets, 5, 247-54 (2005).
144. N.A. Pepas, K.B. Keys, M. Torres-Lugo, et al., PEG-containing hydrogels in drug delivery. J Cont Rel, 62: 81-87 (1999).
145. T. Ooya, J. Lee, K. Park, Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel, J Cont Rel, 5, 121-127 (2003).
146. T. Ooya, J. Lee, K. Park, Hydrotropic dendrimers of generations 4 and 5: Synthesis, characterization, and hydrotropic solubilization of paclitaxel, Bioconj Chem, 151221-151229 (2004).
147. E.R. Gillies, T.B. Jonsson, J.M.K. Fréchet, Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers, J Am Chem Soc, 126, 11936-11943 (2004).
148. E.R. Gillies, J.M.J. Fréchet, Dendrimers and dendritic polymers in drug delivery, DDT, 10, 35-43 (2005).
149. H. Yang, S.T. Lopina, Penicillin V-conjugated PEGPAMAM star polymers, J Biomater Sci, Polym Ed, 14, 1043-1056 (2003).
150. M. Thanou, R. Duncan, Polymer-protein and polymer-drug conjugates in cancer therapy, Cur Opin Invest Drugs, 4, 701-709 (2003).
151. D. Bhadra, S. Bhadra, N.K. Jain, PEGylated peptide-based dendritic nanoparticulate systems for delivery of artemether, J Drug Del Sci Tech, 15, 65-73 (2005).
152. H. Petersen, P.M. Fechner, D. Fischer, et al., Synthesis, characterization, and biocompatibility of polyethylenimine-graftpoly(ethylene glycol) block copolymers, Macromolecules, 35, 6867-6874 (2002).
153. W. Tansey, S. Ke, X.Y. Cao, et al., Synthesis and characterization of branched poly(L-glutamic acid) as a biodegradable drug carrier, J Cont Rel, 94, 39-51 (2004).
154. I. Gitsov, J.M.J. Fréchet, Stimuli-responsive hybrid macromolecules: Novel amphiphilic star copolymers with dendritic groups at the periphery, J Am Chem Soc, 118, 3785-3786 (1996).
155. M. Berna, D. Dalzoppo, G. Pasut, et al., Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: Synthesis, characterization and cellular uptake. Biomacromolecules, 7, 146-153 (2006).
156. B. Qualmann, M.M. Kessels, H.J. Musiol, et al., Synthesis of boron rich lysine dendrimer as protein labels in electron microscopy, Angew Chem Int Ed Engl, 35, 909-911 (1996).
157. J.M. Heldt, N.F. Durand, M. Salmain, et al., Preparation and characterization of poly(amidoamine) dendrimers functionalized with a rhenium carbonyl complex and PEG as new IR probes for carbonyl metallo immunoassay, J Organomet Chem, 689, 4775-482 (2004).
158. Y. Choi, T. Thomas, A. Kotlyar, et al., Synthesis and functional evaluation of DNAassembled polyamidoamine dendrimer clusters for cancer cell-specific targeting, Chem Biol, 12, 35-43 (2005).